GLP-1 receptor agonist weight loss and side effects are partially genetically determined with GLP1R and GIPR variants predicting 6-20% weight loss range and up to 14.8-fold variation in tirzepatide-specific vomiting risk

# PR Review: GLP-1 Pharmacogenomics Claims ## Criterion-by-Criterion Evaluation 1. **Schema** — The new claim file contains all required fields for type:claim (type, domain, confidence, source, created, description, title) with proper formatting, and the enrichment to the existing claim maintains its valid schema. 2. **Duplicate/redundancy** — The new claim introduces genuinely novel evidence about genetic determinants of GLP-1 response (pharmacogenomics) that is distinct from existing claims about population-level adherence, cardiovascular mechanisms, and access patterns; the enrichment to the semaglutide cardiovascular claim adds a complementary genetic mechanism for drug selection that wasn't present in the original claim. 3. **Confidence** — The claim is marked "experimental" which is appropriate given this is a single 2026 study (n=27,885) with validation in one independent EHR dataset but no long-term replication across diverse populations, and the confidence level correctly signals that pharmacogenomic findings require further validation before clinical implementation. 4. **Wiki links** — Multiple wiki links in the `supports` and `related` arrays reference claims not visible in this PR (e.g., "glp-1-access-structure-inverts-need-creating-equity-paradox", "glp1-long-term-persistence-ceiling-14-percent-year-two"), which is expected behavior for cross-PR references and does not affect approval. 5. **Source quality** — The 23andMe Research Institute publishing in Nature 2026 with n=27,885 participants and independent EHR validation represents a credible source for pharmacogenomics claims, though the PR correctly notes the demographic limitations (white, educated, affluent sample) that affect generalizability. 6. **Specificity** — The claim makes falsifiable assertions with specific quantitative predictions (6-20% weight loss range, 14.8-fold variation in vomiting risk, 5-78% nausea/vomiting risk range) that could be contradicted by replication studies showing different effect sizes or lack of genetic association. ## Verdict All criteria pass. The claim presents novel pharmacogenomic evidence with appropriate experimental confidence, proper schema, credible sourcing, and specific falsifiable predictions. The enrichment adds complementary mechanistic insight without redundancy. Broken wiki links are expected cross-PR references. <!-- VERDICT:LEO:APPROVE -->